Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.76
-0.05 (-0.30%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 167.81 | 37.8 | 39.55 | 298.17 | 89.96 | Upgrade
|
| Short-Term Investments | 147.55 | 50.55 | 62.88 | 29.31 | 83.51 | Upgrade
|
| Cash & Short-Term Investments | 315.36 | 88.35 | 102.43 | 327.48 | 173.47 | Upgrade
|
| Cash Growth | 256.94% | -13.74% | -68.72% | 88.79% | -40.78% | Upgrade
|
| Accounts Receivable | 45.54 | 18.44 | 17.47 | 16.79 | 14.07 | Upgrade
|
| Other Receivables | 50 | 50 | - | - | - | Upgrade
|
| Receivables | 95.54 | 68.44 | 17.47 | 16.79 | 14.07 | Upgrade
|
| Prepaid Expenses | 7.56 | 4.28 | 13.64 | 9.2 | 18.81 | Upgrade
|
| Other Current Assets | - | - | - | - | 43.53 | Upgrade
|
| Total Current Assets | 418.46 | 161.07 | 133.54 | 353.46 | 249.87 | Upgrade
|
| Property, Plant & Equipment | 30.27 | 35.77 | 45.36 | 52 | 53.35 | Upgrade
|
| Long-Term Investments | 11.13 | - | - | - | - | Upgrade
|
| Other Long-Term Assets | 25.72 | 157.32 | 203.1 | 201.94 | 71.6 | Upgrade
|
| Total Assets | 485.57 | 354.16 | 382 | 607.4 | 374.82 | Upgrade
|
| Accounts Payable | 2.57 | 2.24 | 1.52 | 1.55 | 3.1 | Upgrade
|
| Accrued Expenses | 19.5 | 13.28 | 12.83 | 20.41 | 37.95 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 16.94 | Upgrade
|
| Current Portion of Leases | 10.95 | 10.71 | 3.92 | 6.75 | 0.5 | Upgrade
|
| Current Income Taxes Payable | 5.29 | 5.85 | - | - | - | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 0.1 | Upgrade
|
| Other Current Liabilities | - | - | 6.49 | - | - | Upgrade
|
| Total Current Liabilities | 38.3 | 32.09 | 24.77 | 28.72 | 58.59 | Upgrade
|
| Long-Term Debt | - | - | - | - | 599.39 | Upgrade
|
| Long-Term Leases | 31.76 | 39.11 | 45.24 | 45.41 | 52.68 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 0.19 | 0.31 | Upgrade
|
| Other Long-Term Liabilities | 118.79 | 107.42 | 99 | 91.29 | 2.42 | Upgrade
|
| Total Liabilities | 188.85 | 178.62 | 169 | 165.6 | 713.39 | Upgrade
|
| Common Stock | 0 | - | - | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,156 | 1,141 | 1,122 | 1,296 | 1,387 | Upgrade
|
| Retained Earnings | -859.63 | -965.52 | -909.1 | -853.91 | -1,726 | Upgrade
|
| Comprehensive Income & Other | 0.06 | 0.01 | -0.07 | -0.02 | - | Upgrade
|
| Shareholders' Equity | 296.72 | 175.55 | 213 | 441.8 | -338.57 | Upgrade
|
| Total Liabilities & Equity | 485.57 | 354.16 | 382 | 607.4 | 374.82 | Upgrade
|
| Total Debt | 42.7 | 49.82 | 49.16 | 52.16 | 669.52 | Upgrade
|
| Net Cash (Debt) | 283.78 | 38.53 | 53.27 | 275.32 | -496.05 | Upgrade
|
| Net Cash Growth | 636.52% | -27.67% | -80.65% | - | - | Upgrade
|
| Net Cash Per Share | 5.51 | 0.79 | 0.96 | 3.74 | -7.14 | Upgrade
|
| Filing Date Shares Outstanding | 51.49 | 49.47 | 48.16 | 62.86 | 74.7 | Upgrade
|
| Total Common Shares Outstanding | 51.07 | 49.47 | 48.09 | 65.23 | 74.44 | Upgrade
|
| Working Capital | 380.16 | 128.98 | 108.77 | 324.75 | 191.28 | Upgrade
|
| Book Value Per Share | 5.81 | 3.55 | 4.43 | 6.77 | -4.55 | Upgrade
|
| Tangible Book Value | 296.72 | 175.55 | 213 | 441.8 | -338.57 | Upgrade
|
| Tangible Book Value Per Share | 5.81 | 3.55 | 4.43 | 6.77 | -4.55 | Upgrade
|
| Machinery | 3.67 | 3.74 | 3.68 | 19.04 | 26.03 | Upgrade
|
| Leasehold Improvements | 25.28 | 25.32 | 26.21 | 24.58 | 24.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.